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Abstract
Objective: Ankaferd® Blood Stopper (ABS) comprises a standardized mixture of the plants Thymus vulgaris, 
Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica. The basic mechanism of action for ABS is the 
formation of an encapsulated protein network that provides focal points for vital erythrocyte aggregation. ABS–
induced protein network formation with blood cells, particularly erythrocytes, covers the primary and secondary 
hemostatic system without disturbing individual coagulation factors. 
Materials and Methods: To understand the effect mechanisms of ABS on hemostasis, a proteomic analysis using 
2D gel electrophoresis and mass spectrometer was performed. 
Results: Proteins of plant origin in Ankaferd® were NADP-dependent-malic enzyme, ribulose bisphosphate-
carboxylase-large chain, maturase K, ATP synthase subunit-beta, ATP synthase subunit-alpha, chalcone-flavanone 
isomerase-1, chalcone-flavanone isomerase-2, and actin-depolymerizing factor. Furthermore, functional proteomic 
studies revealed that proteins resembling human peptides have been detected within Ankaferd®, including ATP 
synthase, mucin-16 (CD164 sialomucin-like 2 protein), coiled-coil domain containing 141 hypothetical protein 
LOC283638 isoform 1, hypothetical protein LOC283638 isoform 2, dynactin 5, complex I intermediate-associated 
protein 30, mitochondrial, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, TP synthase, H+ transporting, 
mitochondrial actin binding 1 isoform, LIM domain and actin binding 1 isoform a, LIM domain and actin binding 1 
isoform b, spectrin alpha non erythrocytic 1, prolactin releasing hormone receptor, utrophin, tet oncogene family 
member 2 isoform b, protein phosphatase 1 regulatory subunit 12A, NIMA (never in mitosis gene a)-related kinase, 
ATP-binding cassette protein C12, Homo sapiens malic enzyme 1, mitochondrial NADP(+)-dependent malic 
enzyme 3, ME2 protein, nuclear factor 1 B-type, abhydrolase domain-containing protein 12B, E3 SUMO-protein 
ligase PIAS2, alpha-1, 2-glucosyltransferase ALG10-A, cofilin, non-muscle isoform, 18 kDa phosphoprotein, p18, 
actin-depolymerizing factor (ADF), twinfilin-1, ankyrin repeat and FYVE domain-containing protein 1, usherin 
precursor, urotensin II receptor, interleukin 4, and midkine. 
Conclusion: Proteomic analysis of Ankaferd® represents a true basis for the upcoming Ankaferd® studies focusing 
on its wound healing, hemostatic, anti-infective, antineoplastic, and preservative biological actions.
(Turk J Hematol 2010; 27: 70-7)
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Ankaferd® Blood Stopper (ABS) is a standardized herbal 
extract obtained from five different plants: Thymus vulgaris, 
Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica 
dioica [1]. Topical safety of ABS in normal healthy human vol-
unteers was shown in a randomized double-blind cross-over 
Phase I clinical trial after preclinical animal studies [2-6]. ABS 
has been approved for local topical applications in external 
post-surgical and post-dental surgery bleedings in Turkey 
(www.Ankaferd.com). Ankaferd has also been used topically 
for the management of hemorrhages uncontrolled by standard 
measures in a wide variety of difficult clinical conditions [7-13]. 
Ankaferd represents its unique local hemostatic effect by pro-
moting the very rapid (<1 s) formation of a protein network, 
which acts as an anchor for vital physiological erythrocyte 
aggregation, covering the classical cascade model of the clot-
ting system without independently acting on coagulation fac-
tors and platelets [1,12]. Unique effects of critical proteins 
inside the ABS on critical transcription factors [14] and in vitro 
anti-infectious [15] and anti-cancer [16,17] effects suggested 
that Ankaferd may also affect pathobiological courses of tis-
sues in addition to its unique action on hemostasis [18]. 
Functional proteomics is the essential step to identify the 
protein library of a given product, such as ABS hemostatic 
agent. The key characteristics of mass analyzers for pro-
teomics are sensitivity, resolution and accuracy. Furthermore, 
demonstrated anti-infectious [15,19] and anti-neoplastic 
[16,17] actions of ABS in vitro represent the basis to search the 
in vivo efficacy and safety of this herbal product for rational 
phytotherapy in upcoming researches. Therefore, the protein 
content of ABS should be searched to proceed with those 
investigations. The aim of this study was to assess functional 
proteomics of ABS via matrix-assisted laser desorption ioniza-
tion-time of flight (MALDI-TOF) analyses.
Materials and Methods 
Two-Dimensional (2D) Sample Preparation
The protein samples for 2D gel electrophoresis were pre-
pared as follows: 200 ml of Ankaferd solution was precipitated 
with trichloroacetic acid (TCA). 100 μl of 100% TCA was added 
for each 1 ml of sample after the vortex and ice bath incubation 
for 15 min and centrifuge at 14,000 g for 10 min at room tem-
perature. The pellet was washed with 1 ml of ice-cold 85% 
acetone, vortexed to disperse pellet, then spun at top speed 
for 5 min at room temperature. The pellet was dried in a Speed 
Vac for 10-20 min to remove residual solvent. The pellet was 
re-suspended in 300 μl of 2D sample rehydration solution con-
taining 7 M urea (Sigma, USA), 2M ThioUrea (Sigma, USA), 
0.2% pH 3-10 linear IPG Ampholyte (Bio-Rad Laboratories, 
USA), 4% CHAPS (Sigma, USA), 1% HED (2-hydroxyethyldi-
sulfide, Sigma, USA), and 1% DTT (Dithiothreitol, Sigma, USA). 
The total protein concentration was measured using the BCA 
protein assay kit (Pierce, Rockford, USA). 
Özet
Amaç: Kanama durdurucu olarak bilinen Ankaferd (AKD); Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia offici-
narum ve Urtica dioica bitki özlerinin özel bir karışımıdır. AKD nin temel etki mekanizması, hayati eritrosit agregasyon
odakları olan enkapsüle protein ağı formasyonunu sağlayarak gerçekleşmektedir. AKD kan hücreleri ve özellikle eritrositler
ile oluşumunu indüklediği protein ağı sayesinde birincil ve ikincil haemostatik sistem üzerine etkisini koagülasyon faktörl-
erini birebir hasarlamadan gerçekleştirir. 
Yöntem ve Gereçler: ABS nin hemostaz üzerindeki etki mekanizmasını anlamak için 2D jel elektroforez ve kütle spe-
ktrometre yöntemleri kullanılarak proteomik analizleri yapıldı.
Bulgular: Ankaferd kanama durdurucu içeriğinde tanımlanan bitkisel proteinler: NADP-bağımlı malik enzim, Ribuloz bis-
fosfatkarboksilaz büyük zinciri, MturazK, ATPsentaz altünitesi beta, ATPsentaz altünitesi-alfa, Chalcon flavonon isomer-
az-1, Chalcon-flavonon izomeraz 2 ve Aktin-depolimerizasyon faktördür. Ayrıca Ankaferd kapsamında koagülasyon için 
oldukça önemli farklı insan proteinleri benzerleri de tanımlanmıştır, bu proteinler arasında; ATP sentaz, musin16 (CD164-
sialomucin-benzer-2 protein), helezonal kangal taşıyan protein-141, hypotetik protein LOC283638 izoform 1, hypothetik 
protein LOC283638 izoform 2, dinaktin 5, Kompleks 1 intermadia ilişikli protein 30, mitokondrial protein, NADH dehidro-
genaz (Ubiquinone) 1 alpha altkompleks, TP sentaz H+ taşıyıcı protein, mitokondrial aktin bağlayıcı protein 1, LIM kangal 
ve aktin bağlayıcı alt ünite 1 izoform a, LIM kangal ve aktin bağlayıcı alt ünite 1 izoform b, Spectrin alpha non eritrotik 1, 
Prolactin releasing hormone reseptör, Utrophin, tet onkogen aile üyesi 2 izoform b, Protein fosfotaz 1 regulatory altünit 
12A, NIMA -ilişkili kinaz, ATP-bağlayıcı protein C12, malik enzim 1, Mitochondrial NADP(+) bağımlı malik enzim 3, ME2 
protein, Nuclear faktör 1B tipi , Abihidrolaz kangal taşıyıcı protein 12B, E3 SUMO-protein ligaz PIAS2, Alpha-1,2-
glucosyltransferase ALG10-A, Cofilin, 18 kDa fosfoprotein, p18, Aktin-depolymerizing faktör, ADF, Twinfilin-1, Ankirin 
tekrarlayan ve FYVE kangalı içeren protein 1, Usherin öncü proteini, Urotensin II reseptör yer almaktadır. 
Sonuç: Proteomik analizler sonucu elde edilen proteinler Ankaferdin hemostatik, yara iyileştirme ve anti-inflamatuvar etkile-
rinin araştırılmasına ışık tutacak ve açıklayıcı olacak niteliktedir. (Turk J Hematol 2010; 27: 70-7) 
Anahtar kelimeler: Ankaferd, proteomiks, hemostaz, kanama
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Figure 2. Spectra acquired from Ankaferd® Blood Stopper via MALDI-TOF
5857771
663.9321
688.1873
943.9321
1177.1566
1209.7771
0
%
500 1000 2000
m/z
Demiralp et al.
Ankaferd® Blood Stopper Turk J Hematol 2010; 27: 70-7 72Two-Dimensional (2D) Gel Electrophoresis of Proteins
During the process, 150 μg of total proteins were rehydrated 
in 300 μl of rehydration buffer overnight (Bio-Rad Laboratories, 
USA). Samples were loaded on first dimension strips (17 cm, pI 
3-10 Linear IPG). The first dimension of isoelectric focusing was 
performed using a Protein IEF cell (Bio-Rad Laboratories, USA). 
After running, first dimension gels were equilibrated for 10 min in 
equilibration buffer I (6 M urea, 0.375 M Tris pH 8.8, 2% SDS, 
20% glycerol, 2% (W/V) DTT (Sigma, USA)), followed by 10 min 
in equilibration buffer II (6 M urea, 0.375 M Tris pH 8.8, 2% SDS, 
20% glycerol, 2.5% (W/V) iodoacetamide). Samples were then 
separated by second dimension on 4-12.5% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)  gels. 
Gels were stained with Sypro Ruby protein stain, and images 
were acquired and analyzed using PDQuest software 8.0 (Bio-
Rad Laboratories, USA). 
Gel Digestion of Proteins
Selected spots from the gel were excised using a Proteome 
Works  Spot Cutter (Bio-Rad Laboratories, USA) and trans-
ferred to  a 96-well plate. The proteins were enzymatically 
digested and  the tryptic peptides ZipTip (Millipore, France) 
purified. After ZipTip purification,  the tryptic peptides were 
eluted from the ZipTip with 3 mg/100μl cyano-4-hydroxycin-
namic acid (CHCA) solution in 50% acetonitrile (ACN)/0.1% 
TriFlora acetic acid and spotted directly onto wax-coated 
MALDI target plates. 
Mass Spectrometry and Database Search
The tryptic peptides on the MALDI target plate were 
analyzed  with MasLynx 4.0, MALDI-time of flight mass 
spectrometer (Waters, UK). Mass spectra were recorded in 
the positive-ion mode. All spectra were acquired with exter-
nal calibration of sub-P, angiotensin, renin, ACTH and glu fib 
mix (Figure 1). PLGS (Waters, UK) was obtained with Swiss-
Prot database with 50 ppm sensitivity. Proteins were evalu-
ated by considering the number  of matched tryptic pep-
tides, the percentage coverage of the  entire protein 
sequence, the apparent molecular weight (MW), and the pI 
of the protein (Figures 2, 3). 
Results
To identify the hemostatic protein contents of ABS herbal 
extract, functional proteomic analysis was performed to shed 
light on the effect mechanisms of ABS on hemostasis. 
Dissolution of proteins was achieved by 2D gel electrophore-
sis. ABS, 1st dimension according to separation pI point and 
2nd dimension separations according to MW, was evaluated 
by making a protein profile map with the help of fluorescent 
staining (Sypro-Ruby). PDQuest program 8.0 (Bio-Rad, USA) 
was used to analyze the protein profiles, and with the 3-D view 
analysis of the separated protein spots, the artifacts were 
eliminated and with the help of Proteome works, the spots 
were resumed from the gels (Figure 4). Proteins were digested 
Figure 3. Spectra of MATK-VITVI acquired via MALDI-TOF
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the range of 500-10.000 daltons. 
In the protein description, MALDI-TOF mass spectrometry, 
which describes m/z values by calculating flight time by matrix-
based laser-dependent ionization, was preferred. The ABS 
protein peptides were analyzed in positive ion mode with exter-
nal calibration and with 50ppm sensitivity by MassLynx4.0 
(Waters, UK). Moreover, the spectra data were identified with 
PLGS (Waters, UK) program using UniProt/ Swiss-Prot data 
banks. Peptide equalizations were re-checked and evaluated 
in accordance with MW and pI with 2D gel electrophoresis 
analyses. Furthermore, the herbal proteins and human-protein-
like proteins were determined in ABS with the PLGS 5-7 PLGS 
score and 89-207 Mascot score.
Regarding the herbal analyses, the herbal proteins identi-
fied in ABS (Table 1) via 2D gel electrophoresis and mass 
spectrometer analysis with MALDI-TOF are:
•  NADP-dependent malic enzyme
•  Ribulose bisphosphate-carboxylase large chain
• Maturase  K
•  ATP synthase beta subunit
•  ATP synthase alpha subunit
•  Chalcone flavanone isomerase-1
•  Chalcone flavanone isomerase 2
•  Actin-depolymerization factor (ADF)
In addition, various human-protein-like proteins that are 
considerably important for hemostasis were also identified 
within ABS (Table 2). It was interesting to see that in addition 
to the herbal proteins, some human-like proteins that could 
represent many crossroads of hemostasis, infection, and neo-
plasia were found within ABS with the proteomic analysis. 
Discussion
In this study, the protein library of Ankaferd has been evalu-
ated via MALDI-TOF analyses. Topical hemostatic efficacy of 
ABS has been previously tested in animals with normal [2,5] 
and defective hemostasis [3,6]. Short-term hematological and 
biochemical safety of the oral systemic administration of 
Ankaferd to rabbits has been shown [20]. No acute mucosal 
toxicity, hematotoxicity, hepatotoxicity, nephrotoxicity, and 
biochemical toxicity was observed during the short-term fol-
low-up of the animals [20]. Those preclinical results reflect a 
starting point to search any possible systemic confounding 
effect of ABS when applied to internal topical surfaces. 
Physiological cell-based coagulation could be clinically man-
aged via topical ABS application to prevent and treat bleeding 
in many distinct clinicopathological states [7-13]. 
Ankaferd-induced formation of the protein network with 
vital erythroid aggregation covers the entire physiological 
hemostatic process. Mainly, there are distinct important com-
ponents of the Ankaferd-induced hemostatic network. Vital 
erythroid aggregation takes place with the spectrin ankyrin and 
actin proteins on the membrane of red blood cells. Based on 
the results of our study, essential erythroid proteins (ankyrin 
recurrent and FYVE bundle containing protein 1, spectrin 
alpha, actin-depolymerization factor, actin-depolymerizing fac-
tor, LIM bundle and actin binding subunit 1 isoform a, LIM 
bundle and actin binding subunit 1 isoform b, NADP-dependent 
malic enzyme, NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, mitochondrial NADP (+) dependent malic enzyme 
3, ribulose bisphosphate- carboxylase large chain, maturase K) 
and the required ATP bioenergy (ATP synthase, ATP synthase 
beta subunit, ATP synthase alpha subunit, ATP-binding protein 
C12, TP synthase H+ transporter protein, ADF, and alpha-1,2-
Table 1. Plant proteins inside the Ankaferd®   
 Description Accession  No    Theoretical  Measured
  Uni ProtKB/Swiss-Prot  pl/Mr  pl/Mr
NADP-dependent malic enzyme  P51615  6/65.18  6.5/75
Rebulose bisphosphatem carboxylase large chain  Q37010  Undef/undef  9.0/100
Mt urase K  Q8HV93  9/62  7.0/55
ATP synthase subunit beta   Q0ZJ13  5.5/53  6.5/50
ATP synthase subunit alpha  Q0ZJ35  5.26/55,5  6.7/53
Chalcone-flavonone isomerase 1  P51117  5.25/25  6.5/35
Actin-depolymerzing factor  Q8SAG3  6.91/16.5  7/12
Figure 4. 3 Dimensional view of protein spots
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of Ankaferd. Ankaferd also upregulates GATA/FOG transcrip-
tion system affecting erythroid functions and urotensin II 
[14,18]. Urotensin II is also an essential component of Ankaferd 
and represents the link between injured vascular endothelium, 
adhesive proteins and active erythroid cells. Those concepts 
could be developed via MALDI-TOF proteomic molecular 
analyses, cytometric arrays, transcription analysis, and 
Scanning electron microscope (SEM) ultrastructural examina-
tions as well as upcoming investigations interacting with basic 
and clinical research facilities.
Ankaferd, in addition to its hemostatic activity, may also 
inhibit the growth of bacteria [19]. The anti-infectious activity 
of Ankaferd may represent an advantage over its current 
clinical use, since it inhibits the growth of bacteria in the area 
used mainly for its hemostatic activity, such as in traumatic 
infected wounds. The antimicrobial activity of Ankaferd was 
tested against many pathogens [15]. The isolates included 
Acinetobacter baumannii, Escherichia coli, Klebsiella pneu-
moniae, Pseudomonas aeruginosa, Enterobacter spp., 
Stenotrophomonas maltophilia, methicillin-resistant 
Staphylococcus aureus (MRSA), methicillin-resistant coagu-
lase negative Staphylococcus,  vancomycin-susceptible 
Enterococcus, and vancomycin-resistant enterococci (VRE). 
Antibacterial activities of Ankaferd against several gram-pos-
itive and gram-negative food and human pathogens were 
also reported in another study [19]. The mechanism of action 
regarding the anti-infective activity of ABS is currently 
unknown. Several proteins (Homo sapiens malic enzyme 1, 
dynactin 5, cofilin, utrophin, mucin 16 (CD164-sialomucin-
Table 2. Proteins resembling human peptides in Ankaferd® protein library
TP synthase, H+ Transporting mitachondrial  A8K0K3  pl: 9.65/11400  8.00/25.000
acting binding 1 isoform  Q9UPN3  pl: 5.27/620.000  5.5/220.000
LIM domain and actin binding 1 isoform a      6.5/50.000
LIM domain and actin binding 1 isoform b      6.5/50.000
Spactirin alpha non erythrocytic 1  Q13813  pl: 5.22/28.400  6.5/40.000
 Prolactin releasing hormone receptor  A5JUU5  pl: 9.43/41.100  9.00/40.000
 Utroptin  P46939 pl:  5.21/40.000  6.5/40.000
tet oncogene family member 2 isoform b      6.5/50.000
 Protein phosphatase 1 regulatory subunit 12A  O14974  pl: 5.31/115.200  6.5/120.000
NIMA never in mitosis gene a)- relatet kinas      
ATP binding cassette protein C12  Q96J65  pl: 8.64/152.000  7.00/150.000
highly similar to Homo sapiens malic enzyme 1  A8K168  pl: 5.79/64.100  6.5/75.000
Mitachondrial NADP (+) - dependent malic enzyme 3  Q6TCH8  pl: 6.31/29.700  6.5/30.000
Me2 protein  Q9BWL6  pl: 8.80/53.500  8.00/50.000
 Nuclear factor 1 B-type  O00712  pl: 9.01/47.400  9.00/50.000
Abhydrolase domain-containing protein 12 B  Q7Z5M8  pl: 8.57/40.000  8.5/50.000
E3 SUMO-protein ligase PIAS2  O75928  pl: 7.47/68.200  7.5/75.000
Alpha- 1,2-glucosyltransferase ALG10-A  Q5BKT4  pl: 9.40/55.600  9.5/70.000
 Cofilin, non-muscle isoform      
18 kDa phosphoprotein     
p18  P23528 pl:  8.26/18.500  8.5/35.000
Actin-depolymerizing factor     
ADF  P60981 pl:  8.12/18.500  8.00/30.000
 Twinfilin-1  Q12792  pl: 5.7/128.200  6,5/120.000
Ankyrin repeat and repeat and FYVE domain containing protein 1  Q9P2R3  pl: 6.47/42.201  7.00/50.000
Usherin [Precursor]  O75445  pl: 6.42/572.200  6.5/220.000
Urotensin II receptor  Q9UKP6  pl: 10.6/42.100  9.57/50.000
IL-4 receptor    
IL-4ligand    
Midkine    
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flavanone isomerase 2, helezonal bundle transporter pro-
tein-141, hypothetical protein LOC283638 isoform 1, hypo-
thetical protein LOC283638 isoform 2, complex I intermedi-
ate-related protein 30) in our proteomic analyses represent an 
important step to elucidate how Ankaferd biologically affects 
the components of numerous pathogens.
Several hypotheses will need to be raised to understand 
the mechanism-of-action of Ankaferd on tumor tissue [16,17]. 
ABS is a hemostatic agent with pleiotropic effects [14,18,21,22]. 
The unique protein library of Ankaferd upregulates critical tran-
scription factors including regulators of neoplasia such as p53 
[14,18]. There is a close relationship between coagulation fac-
tor expressions and solid tumor progression, via mechanisms 
other than angiogenesis. Several proteins (midkine, interleukin 
4, p18, 18 kDa phosphoprotein, SUMO-protein ligase PIAS2, 
abhydrolase bundle transporter protein, the precursor of usher, 
tet oncogene family member 2 isoform b, twinfilin-1, SUMO-
protein ligase PIAS2, prolactin secretor hormone receptor, 
protein phosphatase 1 regulatory subunit 12A, never in mitosis 
gene a (NIMA)-related kinase, mitochondrial protein, mitochon-
drial actin binding protein 1) in our proteomic analyses repre-
sent an important step to elucidate how Ankaferd regulates cell 
cycle and other biological actions of the tumor tissue.
The pleiotropic effects of ABS on vascular endothelium, 
blood cells, angiogenesis, cellular proliferation, vascular 
dynamics, and cellular mediators should be investigated to 
determine its potential role in many pathological states, includ-
ing neoplastic disorders, infectious diseases and inflammation. 
Our proteomic results in this report within many crossroads of 
hemostasis, infection and neoplasia may shed further light and 
represent a novel starting point on that perspective for the new 
avenues of ABS.
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